This study is testing a new medicine called CHS-114 to help people with advanced solid tumors. A tumor is a group of cells that grow too much and can be cancerous. CHS-114 is a special medicine called a monoclonal antibody which targets a part of the body called CCR8. This study is in the early stages (Phase 1) and it's the first time people are trying this medicine.

In the study, there are three parts: one group will get only CHS-114, another group will test how well it works, and the last group will get CHS-114 with another medicine called toripalimab. Toripalimab is another type of medicine that helps the immune system fight cancer.

• This study is for adults 18 years or older.
• Participants will have to meet certain health criteria to join.
• There may be risks like side effects from the medicine.

Before joining, the participants must not have allergies to similar medicines or have had certain surgeries recently. They’ll also need to agree to some health checks and possibly stop some other treatments. The study involves several visits to the doctor and may take some time.